At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients With Relapsed and Refractory Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating External Beam Radiation Therapy and Pembrolizumab for Primary Mediastinal (Thymic) Large B-Cell Lymphoma and 10 related conditions. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This phase II trial studies how well pembrolizumab and external beam radiation therapy work in treating patients with non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and external beam radiation therapy may work better in treating patients with non-Hodgkin lymphoma than pembrolizumab alone.
Study Details
Timeline
Interventions
Undergo EBRT
Given IV